투자판단관련주요경영사항(임상시험계획승인신청) (알츠하이머병 대응 백신 PADIVAX의 제1상 임상시험계획승인 신청(IND))[코]
유바이오로직스· 206650 More filings
Received: 8/18/2026 · Reporter: 유바이오로직스
유바이오로직스는 알츠하이머병 대응 백신 PADIVAX의 제1상 임상시험계획 승인 신청을 했습니다.
🏢 Past 12 months filing pattern (this company)
- Total filings
- 37 filings
- Same category
- 18 filings
- Previous same-category filing
- 7/16/2026(33 days ago)
- Corrections / withdrawals
- 1 filing
Filing source / License
The original PDF/HTML of this filing is provided by FSS DART. MarketBubbles displays only metadata (title, receipt number, type, reporter) and a rule-based summary; we do not mirror the original PDF body (per FSS ToS).